223 related articles for article (PubMed ID: 36570796)
1. Development and comparison of
Wei W; Zhang D; Zhang Y; Li L; Jin Y; An S; Lv C; Zhao H; Wang C; Huang Y; Dong J; Huang G; Liu J
Mol Ther Oncolytics; 2022 Dec; 27():305-314. PubMed ID: 36570796
[TBL] [Abstract][Full Text] [Related]
2.
Qi C; Guo R; Chen Y; Li C; Liu C; Zhang M; Zhang C; Zhang X; Hou X; Chen B; Jia B; Yang Z; Shen L; Zhu H
J Nucl Med; 2024 Jun; 65(6):856-863. PubMed ID: 38604764
[No Abstract] [Full Text] [Related]
3. Annotating BCMA Expression in Multiple Myelomas.
Wei W; Zhang Y; Zhang D; Liu Q; An S; Chen Y; Huang G; Liu J
Mol Pharm; 2022 Oct; 19(10):3492-3501. PubMed ID: 34843261
[TBL] [Abstract][Full Text] [Related]
4. ImmunoPET imaging of human CD8
Zhao H; Wang C; Yang Y; Sun Y; Wei W; Wang C; Wan L; Zhu C; Li L; Huang G; Liu J
J Nanobiotechnology; 2021 Feb; 19(1):42. PubMed ID: 33563286
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers.
Huang W; Liang C; Zhang Y; Zhang D; An S; Wu Q; Li J; Zhao H; Wang C; Cui J; Bao Z; Huang G; Wei W; Liu J
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):380-394. PubMed ID: 37792026
[TBL] [Abstract][Full Text] [Related]
6. GPC3-targeted immunoPET imaging of hepatocellular carcinomas.
An S; Zhang D; Zhang Y; Wang C; Shi L; Wei W; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2682-2692. PubMed ID: 35147737
[TBL] [Abstract][Full Text] [Related]
7. ImmunoPET imaging of multiple myeloma with [
Wang C; Chen Y; Hou YN; Liu Q; Zhang D; Zhao H; Zhang Y; An S; Li L; Hou J; Huang G; Liu J; Zhao YJ; Wei W
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2749-2760. PubMed ID: 33543326
[TBL] [Abstract][Full Text] [Related]
8. ImmunoPET Imaging of CD47 with VHH-Derived Tracers in Pancreatic Cancers.
Liang C; Huang W; Zhang Y; Zhang D; An S; Wu Q; Zhao H; Wang C; Huang G; Wei W; Liu J
Mol Pharm; 2023 Aug; 20(8):4184-4195. PubMed ID: 37403817
[TBL] [Abstract][Full Text] [Related]
9. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
Liu Z; Yan Y; Liu S; Wang F; Chen X
Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A
J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955
[TBL] [Abstract][Full Text] [Related]
11. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
12. Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors.
Chen Y; Hou X; Li D; Ding J; Liu J; Wang Z; Teng F; Li H; Zhang F; Gu Y; Yu S; Qian X; Yang Z; Zhu H
J Pharm Anal; 2023 Apr; 13(4):367-375. PubMed ID: 37181294
[TBL] [Abstract][Full Text] [Related]
13. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.
England CG; Jiang D; Hernandez R; Sun H; Valdovinos HF; Ehlerding EB; Engle JW; Yang Y; Huang P; Cai W
Mol Pharm; 2017 Oct; 14(10):3239-3247. PubMed ID: 28825843
[TBL] [Abstract][Full Text] [Related]
14. Claudin18.2-targeted cancer theranostics.
Zhang D; Huang G; Liu J; Wei W
Am J Nucl Med Mol Imaging; 2023; 13(2):64-69. PubMed ID: 37214268
[TBL] [Abstract][Full Text] [Related]
15. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
Brand C; Longo VA; Groaning M; Weber WA; Reiner T
Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
[TBL] [Abstract][Full Text] [Related]
16. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive Detection of HER2 Expression in Gastric Cancer by
Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
20. Development and comparison of three
Hu G; Zhu W; Liu Y; Wang Y; Zhang Z; Zhu S; Duan W; Zhou P; Fu C; Li F; Huo L
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2634-2644. PubMed ID: 35347439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
